Digital Technologies in Hereditary Coagulation Disorders: A Systematic Review
Hämostaseologie · 01.12.2024 · 44 (06) · 446-458
DOI: 10.1055/a-2415-8646 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Hämostaseologie, erschienen am 01.12.2024. Verfasst von Fabian Kahl und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Digital Medicine, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Digital Technology. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
This systematic review aims to comprehensively survey digital technologies used in the prevention, diagnosis, and treatment of hereditary blood coagulation disorders.
Methods
The systematic review was performed according to the PRISMA guidelines. A systematic search was conducted on PubMed on January 29, 2024. Articles were excluded if they were reviews, meta-analyses, or systematic reviews. Articles were included if they were published from January 1, 2014, onward, written in English, described an actual application of digital tools, were in the context of hereditary coagulation disorders, and involved studies or trials on humans or human data with at least three subjects.
Results
The initial PubMed search on January 29, 2024, identified 2,843 articles, with 672 from January 1, 2014, onward. After screening, 21 articles met the exclusion and inclusion criteria. Among these, 12 focused on artificial intelligence (AI) technologies and 9 on digital applications. AI was predominantly used for diagnosis (five studies) and treatment (four studies), while digital applications were mainly used for treatment (eight studies). Most studies addressed hemophilia A, with a smaller number including hemophilia B or von Willebrand disease.
Discussion
The findings reveal a lack of intervention studies in the prevention, diagnosis, and treatment. However, digital tools, including AI and digital applications, are increasingly used in managing hereditary coagulation disorders. AI enhances diagnostic accuracy and personalizes treatment, while digital applications improve patient care and engagement. Despite these advancements, study biases and design limitations indicate the need for further research to fully harness the potential of these technologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institute for Digital Medicine, University Hospital Bonn, Bonn, Germany.
- TUM School of Computation, Information and Technology, Technical University of Munich, Munich, Germany.
Zitieren
APA
Kahl, F., Kapsecker, M., Nissen, L., Bresser, L., Heinemann, M., Reimer, L. M., & Jonas, S. M. (2024). Digital Technologies in Hereditary Coagulation Disorders: A Systematic Review. Hämostaseologie, 44(06), 446-458. https://doi.org/10.1055/a-2415-8646
Vancouver
Kahl F, Kapsecker M, Nissen L, Bresser L, Heinemann M, Reimer LM, et al. Digital Technologies in Hereditary Coagulation Disorders: A Systematic Review. Hämostaseologie. 2024;44(06):446-458. doi:10.1055/a-2415-8646
BibTeX
@article{Kahl2024,
author = {Kahl, Fabian and Kapsecker, Maximilian and Nissen, Leon and Bresser, Laura and Heinemann, Marie and Reimer, Lara Marie and Jonas, Stephan M},
title = {Digital Technologies in Hereditary Coagulation Disorders: A Systematic Review},
journal = {Hämostaseologie},
year = {2024},
volume = {44},
number = {06},
pages = {446--458},
doi = {10.1055/a-2415-8646}
}
EUVIMED